WHILE surgical excision remains the cornerstone in the management of potentially curable cases of lung cancer, it is depressing to note that this most favourable group of patients has a 5-year survival rate of 25-30% (Stott et al., 1976) .
These patients, suffering from what is considered to be early cancer (i.e. localized to the lung or at most involving the draining lymph nodes) commonly harbour more extensive disease than is revealed by surgery. Indeed a survey of post mortems on these patients dying of post-operative complications within a month of operation revealed that 35%0 harboured residual disease (local plus metastatic) (Mathews et al., 1973) . Some form of additional treatment therefore seems justified.
Chemotherapeutic agents which appear to be active against advanced lung cancer can cause considerable long and shortterm toxicity. These drugs may also be unacceptable to most patients when used in this post-surgical adjuvant role. They can also cause increased morbidity especially when many of these patients are in poor general health. Nor is there any clear evidence that this approach improves survival (Stott et al., 1976) .
Post-operative empyema may improve the prognosis after surgery in lung cancer (Ruckdeschel et al., 1972) . When this action was mimicked using post-operative intrapleural BCG, a similar improvement in prognosis was found, though only in patients with Stage I disease (McKneally et al., 1976) . Sinus hyperplasia in the draining lymph nodes (Black & Speer, 1958) and active macrophages around the primary tumour (Stewart, 1969) apparently indicate a favourable prognosis, and may suggest that the patient's immune system has recognized a tumour-specific antigen and is reacting against it. On the other hand, depression of cell-mediated immunity in advanced malignant disease is both common and of poor prognostic significance (Baldwin et al., 1973; Israel et al., 1973) .
The combination of i.d. or s.c. injections of mixtures of irradiated tumour cells and C. parvum (CP) has been shown to suppress tumour development in a number of animal models. For example, small doses of CP have been combined with s.c. injections of irradiated mouse mastocytoma cells by Stott (1975) and i.d. injections of irradiated mouse fibrosarcoma cells by Bomford (1975) . Both workers reported that this form of treatment produced a strong specific cell-mediated immunity.
Surgical excision of the primary tumour followed by treatment with CP and irradiated tumour cells has been studied in a rat hepatoma model. When treatment was given after excision of the primary tumour there was a reduction in the development and number of lung metastases (Procter et al., 1973) . Even in these animal models the timing of treatment, the route of administration and the respective doses of tumour cells and CP was critical. Indeed Woodruff has highlighted the need for caution in clinical trials based on this animal work and urged that only small doses of CP be used in combined treatment, since large doses may enhance tumour development.
A clinical trial was planned using autologous irradiated lung-cancer cells, which were re-injected into the dermis of the thigh, along with a very small dose of CP during convalescence.
PATIENTS
Ninety-five patients with histologically confirmed cancer of the lung were included in the study. Randomization was carried our peroperatively by the surgeon responsible for the procedure, when he believed that all macroscopic tumour had been resected, and anticipated a relatively smooth post-operative course. Randomization tables were used and slips placed in sealed envelopes which were opened in sequence. Allocation was to a notreatment arm, when routine follow-up alone was carried out, or to treatment with autologous tumour cells. Patients were staged subsequently after pathological analysis of the resected specimens. Stage I patients were those with tumour localized within the lung and Stage II had involvement of the draining nodes but no distant dissemination.
If a patient was randomized to treatment, a sample of fresh tumour was taken immediately from theatre and a cellular suspension prepared under sterile conditions. The method used was similar to that described by Bomford (1975) and no enzymes like collagenase were used to disaggregate the tumour. Fine maceration of the tumour was followed by several washes in Eagle's medium. The final suspension was tested for cell viability by exclusion of trypan blue, a count performed and then stored, after controlled-rate freezing, at -1400C. Tumour cells were recognized on morphological grounds and the resulting suspensions contained 20-30% tumour cells.
Treatment was given during convalescence, 14-28 days after surgery. On the day of treatment a sample containing 20x 106 tumour cells was irradiated with 100 Gy and 30 pg of CP added with medium to a final volume of 1.5 ml.
The trial was approved by the ethics committee of the Oxford Area Health Authority and informed consent was obtained from all patients randomized to immunotherapy.
C. parvum was obtained as a generous gift from Dr T. J. Priestman of the Wellcome Research Foundation, Beckenham, Kent.
RESULTS
A total of 95 patients have been included in the trial, 49 in the control group and 46 in the treatment group. In each group the average age of the patients was similar and patients were predominantly male. Nine out of a total of 14 female patients are in the control group. If all the patients randomised to therapy are considered, then the treatment group shows an apparently poorer survival, but this is not significant (Table I, Fig. 1 ). However, in this group, 12 patients did not receive treatment; 6 patients were either too unwell or died post-operatively; 2 did not attend the follow-up clinic on the day of treatment; 2 were suspected of harbouring residual disease on review, and in 2 a satisfactory cell suspension could not be prepared. Exclusion of the 6 treatment-group and 3 control-group patients who died within 3 months of operation, shows very little difference in survival between the two groups (Table II) . When (Table III) . (0) 7 (5) 1 (0) 1 (0) the control group. Eight of the 13 treatment patients with Stage II tumours are dead at a median time of 9 1 months after operation. This compares with 6 of the 11 control patients with Stage II, who had a median survival of only 6-2 months. Table V shows that there was an even distribution of histological types in the two groups. Although it had been intended to exclude patients with small-cell tumours from this trial, 3 such tumours were diagnosed on the histology of the resected specimens after randomization. These have been included, and the 2 patients with this histology in the treatment group were given immunotherapy. The Table shows (Prehn & Main, 1957) (Mikulski et al., 1979) . BCG, along with irradiated allogeneic tumour cells has been given i.d. to patients suffering from all stages of lung cancer. The results have been compared with groups receiving BCG alone or no additional treatment. There was no benefit from treatment in advanced disease, but patients with Stage I and II disease have not yet been evaluated (Perlin et al., 1977) . The interpretation of the results of this treatment was complicated in Stage III patients as radiotherapy or chemotherapy were added as considered clinically indicated.
Claims of benefit after surgery for Stage III tumours have been made using autologous tumour-cell vaccine treated with Vibrio cholera neuramidase and Concanavalin A injected i.d. with Freund's complete adjuvant. However, as the treatment group of patients required less extensive surgery and had a higher proportion of patients with adenocarcinoma, the interpretation of benefit is doubtful (Takita et al., 1978) .
A controlled randomized trial of intrapleural BCGr in surgically resected lung cancer carried out in this country, failed to confirm the experience of McNeally (Lowe et al., 1980) . The authors point out various minor differences in the treatment given, but it seems unlikely that these were sufficient to explain the differences in the results between the two trials.
By administering a cellular suspension of autologous tumour cells which were irradiated to prevent local implantation or dissemination, and combined with a small dose of CP, it was hoped to augment host resistance to any residual lung tumour. By injecting this vaccine in the thigh where it would drain to lymph nodes unlikely to have had previous exposure to the tumour antigen, and by using CP for its adjuvant effect (Howard et al., 1973) it was hoped that these immunocompetent nodes might produce specific anti-tumour reactivity. Analysis of the results fails to show any such benefit. It does not appear that there have been any adverse effects from this type of therapy, and side effects were minimal.
The overall results of immunotherapy in lung cancer are not encouraging, and we do not feel that any long-term benefit is likely from the approach adopted in this trial. It seems unlikely that this form of treatment will become relevant until lungtumour-specific antigens are identified, assuming that they exist. The recent advances using hybridoma-derived monoclonal antibodies suggest that this may not be such a remote long-term aim (Herlyn, 1979) . 
